Skip to Content
MilliporeSigma
All Photos(3)

Documents

479M-9

Sigma-Aldrich

MDM2 (IF2) Mouse Monoclonal Antibody

Synonym(s):

Mouse double minute protein 2

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

biological source

mouse

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

IF2, monoclonal

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (479M-94)
vial of 0.1 mL concentrate Research Use Only (479M-94-RUO)
vial of 0.5 mL concentrate (479M-95)
vial of 1.0 mL concentrate (479M-96)
vial of 1.0 mL concentrate Research Use Only (479M-96-RUO)
vial of 1.0 mL pre-dilute Research Use Only (479M-97-RUO)
vial of 1.0 mL pre-dilute ready-to-use (479M-97)
vial of 7.0 mL pre-dilute ready-to-use (479M-98)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (479M-98-RUO)

manufacturer/tradename

Cell Marque™

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:50 (concentrated)

isotype

IgG

control

dedifferentiated liposarcoma, well-differentiated liposarcoma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Related Categories

General description

Mouse double minute protein 2 (MDM2) is a gene encoded on the 12q13-14 chromosomal sequence.1-5 It encodes for a 483 amino acid residue protein which binds to the amino-terminal transcription region of p53.2,5 MDM2 has been shown to negatively regulate the tumor-suppressor activity of p53 by three mechanisms: Blocking p53 transcription, binding to p53 causing it to be exported from the nucleus, and accelerating the destruction of p53.1 MDM2 up-regulation has been shown in liposarcoma while being absent in lipoma.2,4 Therefore, anti-MDM2 has been demonstrated to be a potentially useful tool in distinguishing well-differentiated liposarcoma (atypical lipomatous tumor) from lipoma, with the neoplastic cells positive in the former lesion and negative in lipoma.2,4

Quality

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?  

Give our Product Selector Tool a try.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matthieu Bui Nguyen Binh et al.
American journal of clinical pathology, 125(5), 693-697 (2006-05-19)
MDM2 and CDK4 immunostaining can be useful adjuncts in diagnosing liposarcoma among soft tissue neoplasms. We examined the reproducibility of MDM2 and CDK4 staining between 2 laboratories and between tissue microarrays and whole tissue sections. Sixty-two soft tissue tumors were
Stanislava Uhrinova et al.
Journal of molecular biology, 350(3), 587-598 (2005-06-15)
Critical to the inhibitory action of the oncogene product, MDM2, on the tumour suppressor, p53, is association of the N-terminal domain of MDM2 (MDM2N) with the transactivation domain of p53. The structure of MDM2N was previously solved with a p53-derived
A Arici et al.
Indian journal of cancer, 50(3), 164-169 (2013-09-26)
Liposarcomas are among the most common soft tissue sarcomas in adulthood. The purpose of the study is to perform a histopathologic typing according to World Health Organization (WHO) classification of cases diagnosed with liposarcoma and to examine the difference of
P B Aleixo et al.
Journal of clinical pathology, 62(12), 1127-1135 (2009-12-01)
Well differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) have been shown to have supernumerary chromosomes with amplified sequences of the MDM2 and CDK4 genes. MDM2 and CDK4 protein overexpression have also been identified in these tumours. To investigate whether immunohistochemistry
Matthieu Bui Nguyen Binh et al.
The American journal of surgical pathology, 29(10), 1340-1347 (2005-09-15)
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) may be difficult to distinguish from benign adipose tumors and from poorly differentiated sarcomas, respectively. Genetically, they are characterized by amplification of MDM2 and CDK4 genes on chromosome 12q13-15. We examined

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service